Scientists from the Janelia Campus at Howard Hughes Medical Institute have made a surprising discovery, and it might help explain how brain cells communicate long-term changes to each other. Their findings, reported in the journal Cell, describe a new synapse between axons and primary cilia – hair-like structures present on different cell types including neurons.

Synapses normally span between the axon of one neuron and the dendrite of another, however, the new findings suggest that axons could take an alternative, shorter route and connect to special junctions of primary cilia to rapidly signal information to the cell’s nucleus, forming a new kind of synapse not seen before.

“This special synapse represents a way to change what is being transcribed or made in the nucleus, and that changes whole programs,” Janelia Senior Group Leader David Clapham, whose team led the new research, said in a statement.

Novo Nordisk’s recent growth renaissance has arrived thanks in no small part to semaglutide—the GLP-1 molecule behind the company’s leading marketed trio of Ozempic, Rybelsus and Wegovy.

These days, much of the semaglutide hype surrounds Ozempic’s domination in diabetes, plus Wegovy’s potential to stir the slumbering giant that is the global obesity market. But even as the molecule’s metabolic empire prospers, Novo Nordisk isn’t letting its GLP-1 stay in its comfort zone. Novo is also pitting the drug against a pair of elusive targets: nonalcoholic steatohepatitis (NASH) and Alzheimer’s disease.

And while CEO Lars Fruergaard Jørgensen is quick to admit the company’s ambitions in these new diseases are among Novo’s “most risky” R&D endeavors, the payoff for patients could be “tremendous,” he said during a recent interview at Novo Nordisk’s headquarters in Plainsboro, New Jersey.

The promising results led to improved not only cognitive function but also brain connectivity.

An Inserm team at the Lille Neuroscience & Cognition laboratory is working with scientists at Lausanne University Hospital to evaluate the effectiveness of GnRH injection therapy in enhancing cognitive functions in a small group of Down syndrome patients, according to a press release published on Eurekalert.

Down syndrome is the most common chromosomal condition in the United States. According to the Centers for Disease Control and Prevention, about one in every 6,000 babies born in the U.S. has Down syndrome. It causes various symptoms, such as deterioration in cognitive capacity.

Summary: Fentanyl exposure produces specific EEG signatures in the brain. The findings also revealed the drug impairs people’s breathing four minutes before noticeable changes in alertness.

Source: Mass General.

Fentanyl is used to supplement sedation and to relieve severe pain during and after surgery, but it’s also one of the deadliest drugs of the opioid epidemic.

Summary: Study reveals a novel mechanism in locus coeruleus neurons caused by the loss of the GPT2 mitochondrial enzyme that is implicated in the development and progression of neurodegenerative diseases.

Source: Brown University.

The locus coeruleus is among the first brain regions to degenerate in Alzheimer’s and Parkinson’s disease, physicians and scientists have known. But why this area is so vulnerable is less understood.